Navigation Links
Spherix to Raise $1.25 Million in Private Placement
Date:10/26/2011

ducts, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
2. Spherix Announces Annual Shareholders Meeting Date
3. Spherix to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
4. Spherix Regains Compliance With NASDAQ Listing Rule
5. Spherix Announces First Quarter Financial Results
6. Spherix Announces Reverse Stock Split Effective May 6, 2011
7. Spherix to Effect Reverse Stock Split
8. Spherix Announces 2010 Financial Results
9. Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference
10. Spherix to Present at the 13th Annual BIO CEO & Investor Conference
11. Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s resolutions ... care of my furry companion." Nowadays there are pet salons, dog ... to take the little canine or feline darlings along wherever mommy ... some pricey toys at the pet store. But anyone who has ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... has launched PATHT HTS, a new platform for high-throughput ... the microarray industry's annual conference, Chips To Hits in ... the performance of PATH protein microarray slides," said Robert ... BioSurfaces. "PATH HTS was designed to meet the ...
... The NeuronFarm, a developer of Web-based applications intended ... immediate availability of its flagship product, 3D-Readers. , ... third through eighth graders in several school studies, ... automated text scoring, engaging simulations and immediate feedback ...
... As more organizations look at what needs to be ... an area that has come under the spotlight is ... corporate governance issues have become issues even within the ... Act (SOX) has become a reason to organize and ...
Cached Biology Technology:NeuronFarm's 3D-Reader ready to ship 2Sarbox necessitating ECM software, but beware of `best practices' 2Sarbox necessitating ECM software, but beware of `best practices' 3
(Date:4/22/2014)... Consortium Ltd.,s nanotechnology expert will present a poster ... at the 7th International Nanotoxicology Congress to ... , Dr. Monita Sharma will outline a strategy consistent ... of Sciences, " Toxicity Testing in the 21st Century: ... of non-animal methods involving human cells and cell lines ...
(Date:4/22/2014)... presented Beaumont Health System with prestigious, competitive research ... athletic and nonathletic injuries. , The American ... grant to fund stem cell-based research that could ... ruptured knee anterior cruciate ligament, or ACL. According ... cruciate ligament injury is the over-stretching or tearing ...
(Date:4/22/2014)... at the University of Kentucky has discovered new methods ... , The research, led by Peixuan Guo, professor ... the UK College of Pharmacy and Markey Cancer Center, ... Boiling-Resistant Anionic Polymer Material To Build Robust Structures with ... and Daniel L. Jasinski. , The article, which will ...
Breaking Biology News(10 mins):Beaumont awarded grants to study sports-related injury treatment, improve recovery 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2
... has discovered the first identified droplets of spider blood in ... , Two droplets of blood, technically known as haemolymph, have ... - Filistatidae - a family commonly found in South America ... examples of spider blood ever found in an amber fossil. ...
... painkiller prompts brain to release endorphins, bringing real relief ... medicine will relieve pain is enough to prompt the ... painful sensations, a new University of Michigan study finds. ... the brain's own pain-fighting chemicals, called endorphins, play a ...
... completed 60 days of voluntary bedrest in order to ... body. The research team in Toulouse, France, is now ... continue and enhance the research. , At the beginning ... of the WISE study (Women International Simulation Experiment), were ...
Cached Biology News:Spider blood found in 20 million year old fossil 2Thinking the pain away? Study shows the brain's painkillers may cause 'placebo effect' 2Thinking the pain away? Study shows the brain's painkillers may cause 'placebo effect' 3Thinking the pain away? Study shows the brain's painkillers may cause 'placebo effect' 4Female volunteers prepare for a second 'bedrest' 2
Recombinant Rat Leptin, CF...
delta-like 1 homolog (Drosophila)...
... 71-18 mutS and ES1301 mutS are mismatch ... of these strains prevents repair of the ... high mutation efficiencies and making them helpful ... Altered Sites II Mutagenesis Systems. Both ES1301 ...
Request Info...
Biology Products: